Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31177853 | 1.00 | MAPT (0.46) | MAPTCYP1A2LCKGAARECQL | |
| SCHEMBL26140305 | 0.83 | NPSR1 (0.50) | MAPTCYP1A2LCKGAARECQL | |
| SCHEMBL18367820 | 0.81 | MAPT (0.46) | MAPTCYP1A2GAARECQLMAPK1 | |
| SCHEMBL31185912 | 0.81 | MAPT (0.46) | MAPTCYP1A2GAARECQLMAPK1 | |
| SCHEMBL29790224 | 0.80 | MAPT (0.45) | MAPTCYP1A2GAARECQLMAPK1 | |
| SCHEMBL15972630 | 0.80 | MAPT (0.45) | MAPTCYP1A2GAARECQLMAPK1 | |
| SCHEMBL4879193 | 0.80 | MAPT (0.45) | MAPTCYP1A2GAARECQLMAPK1 | |
| SCHEMBL30342124 | 0.80 | MAPT (0.45) | MAPTCYP1A2GAARECQLMAPK1 | |
| SCHEMBL7107317 | 0.80 | CTSA (0.47) | MAPTCYP1A2GAARECQLMAPK1 | |
| SCHEMBL318417 | 0.80 | MAPT (0.45) | MAPTCYP1A2GAARECQLMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| CN-117715905-A | Checkpoint kinase 1 (CHK 1) inhibitors and uses thereof | 无界生物公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-4141002-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11572366-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| CN-109641885-B | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2022-09-30 | — | — | CN | disclosed |
| US-11453652-B2 | Di-macrocycles | LUMIPHORE, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20120108611-A1 | 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS | 2012-05-03 | — | — | US | disclosed |
| US-8110579-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists | SANOFI-AVENTIS (FR) | 2012-02-07 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110189088-A1 | RADIOPHARMACEUTICAL COMPLEXES | LUMIPHORE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110189088-A1 | RADIOPHARMACEUTICAL COMPLEXES | LUMIPHORE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011079291-A1 | RADIOPHARMACEUTICAL COMPLEXES | LUMIPHORE, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011007091-A1 | DERIVATIVES OF 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS UROTENSIN-II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-20 | — | — | WO | disclosed |
| US-20110009426-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-20090318473-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI AVENTIS | 2009-12-24 | — | — | US | disclosed |
| CN-101511789-A | 5, 6-bisaryl-2-pyridine-carboxamide derivatives, their preparation and their use in therapy as urotensin II receptor antagonists | SANOFI AVENTIS (FR) | 2009-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318473-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | MAPT 3323/4885CYP1A2 1839/4885LCK 2319/4885 |
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | CD38, BCL9, BCL6B | MAPT 4130/4885CYP1A2 1954/4885LCK 333/4885 |
| US-20110009426-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | MAPT 3580/4885CYP1A2 2043/4885LCK 2596/4885 |
| US-20110189088-A1 | RADIOPHARMACEUTICAL COMPLEXES | SLC39A3, SLC30A5, SLC40A1 | MAPT 4451/4885CYP1A2 4428/4885LCK 2836/4885 |
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | MAPT 3192/4885CYP1A2 4796/4885LCK 622/4885 |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, CHEK2, RAD1 | MAPT 3192/4885CYP1A2 4796/4885LCK 622/4885 |
| US-11453652-B2 | Di-macrocycles | DLD, NDC1, MCL1 | MAPT 1196/4885CYP1A2 1433/4885LCK 744/4885 |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | MAPT 971/4885CYP1A2 1331/4885LCK 3224/4885 |
| US-20120108611-A1 | 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | MAPT 3323/4885CYP1A2 1839/4885LCK 2319/4885 |
| US-11572366-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | MAPT 4651/4885CYP1A2 330/4885LCK 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.